Document type
OtherVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/206265
Emerging issues on Staphylococcus aureus endocarditis and the role in therapy of daptomycin plus fosfomycin
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
IntroductionMethicillin-resistant and -susceptible Staphylococcus aureus (MRSA/MSSA) infections are a major global health-care problem. Bacteremia with S. aureus exhibits high rates of morbidity and mortality and can cause complicated infections such as infective endocarditis (IE). The emerging resistance profile of S. aureus is worrisome, and several international agencies have appealed for new treatment approaches to be developed.Areas coveredDaptomycin presents a rapid bactericidal effect against MRSA and has been considered at least as effective as vancomycin in treating MRSA bacteremia. However, therapy failure is often related to deep-seated infections, e.g. endocarditis, with high bacterial inocula and daptomycin regimens S. aureus infections have limitations in monotherapy. Daptomycin in combination with other antibiotics, e.g. fosfomycin, may be effective in improving clinical outcomes in patients with MRSA IE.Expert opinionExploring therapeutic combinations has shown fosfomycin to have a unique mechanism of action and to be the most effective option in preventing the onset of resistance to and optimizing the efficacy of daptomycin, suggesting the synergistic combination of fosfomycin with daptomycin is a useful alternative treatment option for MSSA or MRSA IE.
Subject (English)
Citation
Citation
GARCÍA DE LA MÀRIA, Cristina, et al. Emerging issues on Staphylococcus aureus endocarditis and the role in therapy of daptomycin plus fosfomycin. Expert Review Of Anti-Infective Therapy. 2023. Vol. 21, num. 3, pags. 281-293. ISSN 1744-8336. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/206265